Key Takeaways Intuitive Surgical's Q1 2025 revenues rose 19% to $2.25B, with EPS beating expectations. ISRG faces global CapEx headwinds and rising U.S. MIS robotics competition from MDT and GMED. da Vinci 5's clinical value and 85% recurring revenues help ISRG defend its share amid pricing pressure.Intuitive Surgical (ISRG) delivered a robust first-quarter 2025, with revenues rising 19% year over year to $2.25 billion and earnings per share (EPS) surpassing expectations. Yet, even as the company celebrat ...

Significant Development Supports Long-Term Global Commercial Strategy of the LIBERTY® SystemHINGHAM, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY Endovascular Robotic System, announced that it has been granted a critical patent in China by the China National Intellectual Property Administration (CNIPA), a key step in the Company’s global IP expansion strategy. The patent, which covers the robotic manipulation of a surgical tool handle, fu ...

The addition of the head of Sales Operations & Analytics aims to strengthen sales infrastructure and launch executionHINGHAM, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY Endovascular Robotic System, today announced the continued expansion of its commercial team in preparation for the anticipated U.S. launch of the LIBERTY System, which is projected during the third quarter of 2025. The Company remains actively engaged with the U.S. Food ...

Receives FDA Clearance for the mBôs™ TKA System Groundbreaking Trial Set to Deliver one of the World’s First Autonomous Saw-Based Robotic TKA Surgeries on Live Patients Management to Host Business Update Conference Call Today at 4:30 p.m. Eastern Time AUSTIN, Texas, May 14, 2025 (GLOBE NEWSWIRE) -- Monogram Technologies Inc. (NASDAQ: MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and ...

ST. LOUIS, May 12, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2025. “We’ve started the year with solid execution on key commercial and innovation efforts,” said David Fischel, Chairman and CEO. “This is a milestone rich year in which we are beginning to demonstrate the tangible reality and commercial impact of our comprehensive inno ...